VYNE 13G: Zhang Xiaofan reports 1.87M shares

VYNE Therapeutics Inc. Schedule 13G: Zhang Xiaofan reports beneficial ownership of 1,873,388 shares of common stock, representing 5.6% of the class as of 06/08/2026.

Rhea-AI Filing Summary

VYNE Therapeutics Inc. Schedule 13G: Zhang Xiaofan reports beneficial ownership of 1,873,388 shares of common stock, representing 5.6% of the class as of 06/08/2026. The filer states sole voting and dispositive power over the 1,873,388 shares. The signature on the filing is dated 06/15/2026.

Insights

Equity Ownership Analyst

13G shows a passive investor reporting a substantial 5.6% stake.

The filing lists 1,873,388 shares beneficially owned as of 06/08/2026 with sole voting and dispositive power. As a Schedule 13G, this is a disclosure of ownership rather than an active transaction.

Timing and intent language typical of a 13G is not included in the excerpt; subsequent filings would specify any change from passive to active ownership.

Corporate Governance Expert

Filer holds direct control over the reported shares, which may affect proxy voting dynamics.

The record shows sole voting power and sole dispositive power for the 1,873,388 shares, which equals 5.6% of the class. That level can make the holder relevant in shareholder votes or discussions.

Whether this triggers additional disclosures or agreements is not stated in the excerpt; monitoring subsequent filings could clarify any changes.

Key Figures

Filing type: Schedule 13G Shares beneficially owned: 1,873,388 shares Percent of class: 5.6% +2 more

5 metrics

Filing type Schedule 13G ownership disclosure for common stock

Shares beneficially owned 1,873,388 shares reported beneficial ownership as of <date>06/08/2026</date>

Percent of class 5.6% percent of common stock represented by the reported shares

CUSIP 92941V308 VYNE Therapeutics Inc. common stock identifier

Signature date 06/15/2026 date the filer signed the Schedule 13G

Key Terms

Schedule 13G, Beneficially owned, Sole dispositive power, Sole voting power

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: VYNE Therapeutics Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Item 4. (a) Amount beneficially owned: 1,873,388"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Item 4. (c)(iii) Sole power to dispose or to direct the disposition of: 1,873,388"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Sole voting power regulatory

"Item 4. (c)(i) Sole power to vote or to direct the vote: 1,873,388"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Zhang Xiaofan's Schedule 13G for VYNE (VYNE) report?

It reports beneficial ownership of 1,873,388 shares, equal to 5.6% of VYNE's common stock. The filing states sole voting and dispositive power over those shares and includes a signature dated 06/15/2026.

Does the Schedule 13G show Zhang Xiaofan has voting control over VYNE shares?

Yes. The filing states sole voting power and sole dispositive power for 1,873,388 shares. This indicates the filer controls voting and disposition of the reported shares as disclosed.

What percentage of VYNE does the reported holding represent?

The filing lists the position as 5.6% of the class. The percentage is specifically tied to the 1,873,388 shares reported as beneficially owned as of 06/08/2026.

Is the Schedule 13G an active trade or a static ownership disclosure for VYNE?

A Schedule 13G is a disclosure of beneficial ownership rather than an active trade. It reports a stake of 1,873,388 shares and does not by itself indicate a market transaction.

What dates appear on the filing and signature for the VYNE 13G?

The document shows the ownership date line as 06/08/2026 and the signature by Zhang Xiaofan dated 06/15/2026. Those are the dates provided in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 02:24 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

VYNE Therapeutics Inc.

(Name of Issuer)

common stock, par value $0.0001

(Title of Class of Securities)

92941V308

(CUSIP Number)

06/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92941V308

1

Names of Reporting Persons

Zhang Xiaofan

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

HONG KONG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,873,388.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,873,388.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,873,388.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VYNE Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NEW JERSEY, 08807
Item 2.
(a)	Name of person filing: Zhang Xiaofan
(b)	Address or principal business office or, if none, residence: Room 1607, Tower 3, Central Residence, 1038 Huashan Road, Shanghai
(c)	Citizenship: Hong Kong, China
(d)	Title of class of securities: common stock, par value $0.0001
(e)	CUSIP Number(s): 92941V308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,873,388
(b)	Percent of class: 5.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,873,388
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,873,388
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Zhang Xiaofan

Signature:	Zhang Xiaofan
Name/Title:	Mr.
Date:	06/15/2026